Systemic inflammation in patients with chronic obstructive pulmonary disease undergoing percutaneous coronary intervention

Background and objective Systemic inflammation plays an important role in both chronic obstructive pulmonary disease ( COPD ) and coronary artery disease ( CAD ). The purpose of the present study was to assess the association of high‐sensitivity C ‐reactive protein (hs‐ CRP ), a biomarker of systemic inflammation, with in‐hospital outcomes in patients with COPD undergoing percutaneous coronary intervention ( PCI ). Methods A total of 378 patients with COPD who were treated with PCI from J anuary 2007 through J anuary 2012, were divided into two groups according to hs‐ CRP level at admission. Demographics, clinical, angiographic data and in‐hospital outcomes were compared. Results Patients with elevated hs‐ CRP (≥3 mg/L) were more likely to be female and current smokers, had more severe airflow limitation, more hypertension, diabetes and cardiac dysfunction and had increased incidence of three‐vessel disease and more type C lesions. Subjects with elevated hs‐ CRP were also less likely to have been prescribed with statins and B ‐blockers, perhaps. Rate of in‐hospital composite major adverse cardiovascular events ( MACE s) was higher (15.5% vs 8.2%, P  = 0.041) and hospital stay was longer (8.2 ± 2.0 vs 7.5 ± 1.7 days, P  < 0. 001) in patients with elevated hs‐ CRP . A combined analysis of MACE on the basis of airflow limitation and hs‐ CRP showed an exaggerated hazard ratio in the presence of both severe airflow limitation and elevated hs‐ CRP . In a multivariate analysis, elevated periprocedural hs‐ CRP was independently related with MACE s and hospital stay. Conclusions Elevated periprocedural hs‐ CRP is independently and additively related with increased incidence of in‐hospital adverse outcomes in COPD patients undergoing PCI .